Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07612631 · ClinicalTrials.gov registry record · Early Phase 1
Imaging CRF X NOP Interactions in Alcohol Use Disorder
A Early Phase 1 study, sponsored by Rajesh Narendran.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
NCT07612631 is a Early Phase 1 study that is actively recruiting participants, run by Rajesh Narendran. The registered enrollment target is 90 participants.
The verdict
NCT07612631, a Early Phase 1 study, is actively recruiting participants, sponsored by Rajesh Narendran.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This positron emission tomography imaging study uses \[C-11\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in a relapse to alcohol.
Interventions
- DRUG Hydrocortisone
- RADIATION Baseline [C-11]NOP-1A PET scan
- RADIATION Post-hydrocortisone [C-11]NOP-1A PET scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07612631
The ClinicalTrials.gov registry entry for NCT07612631 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rajesh Narendran, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hydrocortisone is the first listed.
NCT07612631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07612631 about?
NCT07612631 is a clinical study titled "Imaging CRF X NOP Interactions in Alcohol Use Disorder". This positron emission tomography imaging study uses \[C-11\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in a relapse to alcohol.
What is the current status of trial NCT07612631?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2026-06-01. Estimated completion is 2032-06-30.
What interventions are being tested in trial NCT07612631?
The interventions under investigation include: Hydrocortisone (DRUG), Baseline [C-11]NOP-1A PET scan (RADIATION), Post-hydrocortisone [C-11]NOP-1A PET scan (RADIATION).
Who is sponsoring clinical trial NCT07612631?
This trial is sponsored by Rajesh Narendran, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.